Daewoong takes a lead for anticancer ‘Samfenet’ on behalf of Samsung Bioepis

Published: 2018-03-07 14:39:38

Updated: 2018-03-07 14:39:38

Daewoong Pharmaceutical(CEO Jong-Wook Lee) announced the company would launch ‘Samfenet,’ a Samsung Bioepis’ trastuzumab biosimilar on the 5^th in Korea. Samfenet acquired approval from the Korean Ministry of Food and Drug Safety on 8 November 2017, and was registered in the list of insured products for the National Health Insurance Service last February.

Samfenet is a biosimilar referring ‘Her...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.